Beam Therapeutics Management
Management criteria checks 4/4
Beam Therapeutics' CEO is John Evans, appointed in Apr 2017, has a tenure of 7.92 years. total yearly compensation is $6.28M, comprised of 10.9% salary and 89.1% bonuses, including company stock and options. directly owns 1.04% of the company’s shares, worth $19.72M. The average tenure of the management team and the board of directors is 5.2 years and 4.2 years respectively.
Key information
John Evans
Chief executive officer
US$6.3m
Total compensation
| CEO salary percentage | 10.9% |
| CEO tenure | 7.9yrs |
| CEO ownership | 1.0% |
| Management average tenure | 5.2yrs |
| Board average tenure | 4.2yrs |
Recent management updates
Recent updates
Upgrading Beam Therapeutics: Promising BEAM-302 Data Opens Door For Durable Gene Therapy
Mar 21Beam Therapeutics: Single-Base Editing Seems To Work
Mar 10Beam Therapeutics Inc.'s (NASDAQ:BEAM) Prospects Need A Boost To Lift Shares
Jan 31
Beam Therapeutics: Too Expensive For Me, But Watch For Important Catalysts
Jan 22Here's Why We're Not At All Concerned With Beam Therapeutics' (NASDAQ:BEAM) Cash Burn Situation
Dec 20Beam Therapeutics: Additional BEAM-101 And ESCAPE Tech Data At ASH 2024 Makes This A Watch
Nov 07Insufficient Growth At Beam Therapeutics Inc. (NASDAQ:BEAM) Hampers Share Price
Oct 28Beam Therapeutics: Still Holding Fast To Generous Valuation, Still Not A Buy
Sep 29We're Not Worried About Beam Therapeutics' (NASDAQ:BEAM) Cash Burn
Sep 04Beam Therapeutics Inc.'s (NASDAQ:BEAM) Prospects Need A Boost To Lift Shares
Jul 12Beam Therapeutics: Slow Developmental Progress, But Promising Potential
Jul 01We're Not Worried About Beam Therapeutics' (NASDAQ:BEAM) Cash Burn
May 13Beam Therapeutics: A 'Hold' Amid High Valuation And Uncertain Revenue Prospects
Apr 24Lacklustre Performance Is Driving Beam Therapeutics Inc.'s (NASDAQ:BEAM) Low P/S
Apr 07Beam Therapeutics Inc. (NASDAQ:BEAM) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Mar 01Things Look Grim For Beam Therapeutics Inc. (NASDAQ:BEAM) After Today's Downgrade
Feb 29Beam Therapeutics: Cool Tech, But At A Way Inflated Price For Now
Feb 08This Just In: Analysts Are Boosting Their Beam Therapeutics Inc. (NASDAQ:BEAM) Outlook for This Year
Nov 01We're Hopeful That Beam Therapeutics (NASDAQ:BEAM) Will Use Its Cash Wisely
Jul 23Here's Why We're Not At All Concerned With Beam Therapeutics' (NASDAQ:BEAM) Cash Burn Situation
Apr 08Industry Analysts Just Made A Massive Upgrade To Their Beam Therapeutics Inc. (NASDAQ:BEAM) Revenue Forecasts
Nov 08Beam Therapeutics: Now Is Not The Right Time To Own
Sep 15Beam Therapeutics GAAP EPS of -$1.02 misses by $0.05, revenue of $16.65M beats by $7.21M
Aug 09Beam drops 19% as FDA issues clinical hold on blood cancer candidate
Aug 01Revisiting Beam Therapeutics Among Collaborative Catalysts
Jul 10Newsflash: Beam Therapeutics Inc. (NASDAQ:BEAM) Analysts Have Been Trimming Their Revenue Forecasts
May 10CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2024 | n/a | n/a | -US$377m |
| Sep 30 2024 | n/a | n/a | -US$144m |
| Jun 30 2024 | n/a | n/a | -US$143m |
| Mar 31 2024 | n/a | n/a | -US$135m |
| Dec 31 2023 | US$6m | US$685k | -US$133m |
| Sep 30 2023 | n/a | n/a | -US$314m |
| Jun 30 2023 | n/a | n/a | -US$327m |
| Mar 31 2023 | n/a | n/a | -US$316m |
| Dec 31 2022 | US$9m | US$650k | -US$289m |
| Sep 30 2022 | n/a | n/a | -US$315m |
| Jun 30 2022 | n/a | n/a | -US$234m |
| Mar 31 2022 | n/a | n/a | -US$238m |
| Dec 31 2021 | US$14m | US$590k | -US$371m |
| Sep 30 2021 | n/a | n/a | -US$401m |
| Jun 30 2021 | n/a | n/a | -US$408m |
| Mar 31 2021 | n/a | n/a | -US$366m |
| Dec 31 2020 | US$907k | US$529k | -US$196m |
| Sep 30 2020 | n/a | n/a | -US$132m |
| Jun 30 2020 | n/a | n/a | -US$119m |
| Mar 31 2020 | n/a | n/a | -US$106m |
| Dec 31 2019 | US$2m | US$473k | -US$91m |
| Sep 30 2019 | n/a | n/a | -US$86m |
| Jun 30 2019 | n/a | n/a | -US$134m |
| Mar 31 2019 | n/a | n/a | -US$124m |
| Dec 31 2018 | US$4m | US$441k | -US$117m |
Compensation vs Market: John's total compensation ($USD6.28M) is about average for companies of similar size in the US market ($USD5.36M).
Compensation vs Earnings: John's compensation has been consistent with company performance over the past year.
CEO
John Evans (46 yo)
7.9yrs
Tenure
US$6,280,099
Compensation
Mr. John M. Evans, M.B.A., is CEO & Director of Beam Therapeutics Inc. from January 2020. He joined the Beam Therapeutics Inc. in 2017. He was President, CEO & Director of Beam Therapeutics Inc. until Janu...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 7.9yrs | US$6.28m | 1.04% $ 19.7m | |
| President | 5.2yrs | US$2.79m | 0.12% $ 2.3m | |
| Senior VP | 5.9yrs | US$2.28m | 0.056% $ 1.1m | |
| Chief Medical Officer | 4yrs | US$2.55m | 0.0017% $ 31.9k | |
| Co-Founder | no data | no data | no data | |
| Co-Founder | no data | no data | no data | |
| Co-Founder | no data | no data | no data | |
| Chief Financial Officer | less than a year | no data | no data | |
| Chief Technology Officer | no data | no data | no data | |
| Chief Scientific Officer | 2yrs | no data | no data | |
| Vice President of Investor Relations & External Communications | no data | no data | no data | |
| Chief Human Resources Officer | 7.6yrs | no data | no data |
5.2yrs
Average Tenure
56.5yo
Average Age
Experienced Management: BEAM's management team is seasoned and experienced (5.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | no data | US$6.28m | 1.04% $ 19.7m | |
| Independent Director | 3.3yrs | US$435.22k | 0% $ 0 | |
| Independent Lead Director | 6.8yrs | US$465.22k | 0.021% $ 396.3k | |
| Independent Director | 5.4yrs | US$450.22k | 0% $ 0 | |
| Independent Director | 4.2yrs | US$447.72k | 0% $ 0 | |
| Director | less than a year | no data | no data | |
| Independent Director | 1.3yrs | US$772.68k | no data | |
| Independent Director | 6.3yrs | US$442.72k | 0% $ 0 |
4.2yrs
Average Tenure
57yo
Average Age
Experienced Board: BEAM's board of directors are considered experienced (4.2 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/24 02:51 |
| End of Day Share Price | 2025/03/21 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Beam Therapeutics Inc. is covered by 23 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Huidong Wang | Barclays |
| Konstantinos Biliouris | BMO Capital Markets Equity Research |
| Alec Stranahan | BofA Global Research |